446 related articles for article (PubMed ID: 21377995)
21. Downregulation of BRCA1-BRCA2-containing complex subunit 3 sensitizes glioma cells to temozolomide.
Chai KM; Wang CY; Liaw HJ; Fang KM; Yang CS; Tzeng SF
Oncotarget; 2014 Nov; 5(21):10901-15. PubMed ID: 25337721
[TBL] [Abstract][Full Text] [Related]
22. Gene expression profiling predicts response to temozolomide in malignant gliomas.
Yoshino A; Ogino A; Yachi K; Ohta T; Fukushima T; Watanabe T; Katayama Y; Okamoto Y; Naruse N; Sano E; Tsumoto K
Int J Oncol; 2010 Jun; 36(6):1367-77. PubMed ID: 20428759
[TBL] [Abstract][Full Text] [Related]
23. Regulation of temozolomide resistance in glioma cells via the RIP2/NF-κB/MGMT pathway.
Hu YH; Jiao BH; Wang CY; Wu JL
CNS Neurosci Ther; 2021 May; 27(5):552-563. PubMed ID: 33460245
[TBL] [Abstract][Full Text] [Related]
24. Inhibition of telomerase activity in malignant glioma cells correlates with their sensitivity to temozolomide.
Kanzawa T; Germano IM; Kondo Y; Ito H; Kyo S; Kondo S
Br J Cancer; 2003 Sep; 89(5):922-9. PubMed ID: 12942127
[TBL] [Abstract][Full Text] [Related]
25. Combined treatment with temozolomide and methoxyamine: blocking apurininc/pyrimidinic site repair coupled with targeting topoisomerase IIalpha.
Yan L; Bulgar A; Miao Y; Mahajan V; Donze JR; Gerson SL; Liu L
Clin Cancer Res; 2007 Mar; 13(5):1532-9. PubMed ID: 17332299
[TBL] [Abstract][Full Text] [Related]
26. Distinct molecular mechanisms of acquired resistance to temozolomide in glioblastoma cells.
Happold C; Roth P; Wick W; Schmidt N; Florea AM; Silginer M; Reifenberger G; Weller M
J Neurochem; 2012 Jul; 122(2):444-55. PubMed ID: 22564186
[TBL] [Abstract][Full Text] [Related]
27. PARP-mediated PARylation of MGMT is critical to promote repair of temozolomide-induced O6-methylguanine DNA damage in glioblastoma.
Wu S; Li X; Gao F; de Groot JF; Koul D; Yung WKA
Neuro Oncol; 2021 Jun; 23(6):920-931. PubMed ID: 33433610
[TBL] [Abstract][Full Text] [Related]
28. ABT-888 enhances cytotoxic effects of temozolomide independent of MGMT status in serum free cultured glioma cells.
Balvers RK; Lamfers ML; Kloezeman JJ; Kleijn A; Berghauser Pont LM; Dirven CM; Leenstra S
J Transl Med; 2015 Feb; 13():74. PubMed ID: 25886061
[TBL] [Abstract][Full Text] [Related]
29. Valproic acid downregulates the expression of MGMT and sensitizes temozolomide-resistant glioma cells.
Ryu CH; Yoon WS; Park KY; Kim SM; Lim JY; Woo JS; Jeong CH; Hou Y; Jeun SS
J Biomed Biotechnol; 2012; 2012():987495. PubMed ID: 22701311
[TBL] [Abstract][Full Text] [Related]
30. Inhibition of GSH synthesis potentiates temozolomide-induced bystander effect in glioblastoma.
Kohsaka S; Takahashi K; Wang L; Tanino M; Kimura T; Nishihara H; Tanaka S
Cancer Lett; 2013 Apr; 331(1):68-75. PubMed ID: 23246370
[TBL] [Abstract][Full Text] [Related]
31. The Antiproliferative and Pro-apoptotic Effects of Methoxyamine on Pediatric Medulloblastoma Cell Lines Exposed to Ionizing Radiation and Chemotherapy.
Pezuk JA; Valera ET; Delsin LE; Scrideli CA; Tone LG; Brassesco MS
Cent Nerv Syst Agents Med Chem; 2015; 16(1):67-72. PubMed ID: 26553097
[TBL] [Abstract][Full Text] [Related]
32. Inhibition of prolyl 4-hydroxylase, beta polypeptide (P4HB) attenuates temozolomide resistance in malignant glioma via the endoplasmic reticulum stress response (ERSR) pathways.
Sun S; Lee D; Ho AS; Pu JK; Zhang XQ; Lee NP; Day PJ; Lui WM; Fung CF; Leung GK
Neuro Oncol; 2013 May; 15(5):562-77. PubMed ID: 23444257
[TBL] [Abstract][Full Text] [Related]
33. mTOR inhibition and levels of the DNA repair protein MGMT in T98G glioblastoma cells.
Smalley S; Chalmers AJ; Morley SJ
Mol Cancer; 2014 Jun; 13():144. PubMed ID: 24909675
[TBL] [Abstract][Full Text] [Related]
34. NVP-BEZ235, a novel dual PI3K-mTOR inhibitor displays anti-glioma activity and reduces chemoresistance to temozolomide in human glioma cells.
Yu Z; Xie G; Zhou G; Cheng Y; Zhang G; Yao G; Chen Y; Li Y; Zhao G
Cancer Lett; 2015 Oct; 367(1):58-68. PubMed ID: 26188279
[TBL] [Abstract][Full Text] [Related]
35. Riluzole enhances the antitumor effects of temozolomide via suppression of MGMT expression in glioblastoma.
Yamada T; Tsuji S; Nakamura S; Egashira Y; Shimazawa M; Nakayama N; Yano H; Iwama T; Hara H
J Neurosurg; 2020 Mar; 134(3):701-710. PubMed ID: 32168477
[TBL] [Abstract][Full Text] [Related]
36. Apoptosis in malignant glioma cells triggered by the temozolomide-induced DNA lesion O6-methylguanine.
Roos WP; Batista LF; Naumann SC; Wick W; Weller M; Menck CF; Kaina B
Oncogene; 2007 Jan; 26(2):186-97. PubMed ID: 16819506
[TBL] [Abstract][Full Text] [Related]
37. GANT61, a GLI inhibitor, sensitizes glioma cells to the temozolomide treatment.
Li J; Cai J; Zhao S; Yao K; Sun Y; Li Y; Chen L; Li R; Zhai X; Zhang J; Jiang C
J Exp Clin Cancer Res; 2016 Nov; 35(1):184. PubMed ID: 27894350
[TBL] [Abstract][Full Text] [Related]
38. ATM regulates 3-methylpurine-DNA glycosylase and promotes therapeutic resistance to alkylating agents.
Agnihotri S; Burrell K; Buczkowicz P; Remke M; Golbourn B; Chornenkyy Y; Gajadhar A; Fernandez NA; Clarke ID; Barszczyk MS; Pajovic S; Ternamian C; Head R; Sabha N; Sobol RW; Taylor MD; Rutka JT; Jones C; Dirks PB; Zadeh G; Hawkins C
Cancer Discov; 2014 Oct; 4(10):1198-213. PubMed ID: 25100205
[TBL] [Abstract][Full Text] [Related]
39. N-methylpurine DNA glycosylase inhibits p53-mediated cell cycle arrest and coordinates with p53 to determine sensitivity to alkylating agents.
Song S; Xing G; Yuan L; Wang J; Wang S; Yin Y; Tian C; He F; Zhang L
Cell Res; 2012 Aug; 22(8):1285-303. PubMed ID: 22801474
[TBL] [Abstract][Full Text] [Related]
40. Alkylation sensitivity screens reveal a conserved cross-species functionome.
Svilar D; Dyavaiah M; Brown AR; Tang JB; Li J; McDonald PR; Shun TY; Braganza A; Wang XH; Maniar S; St Croix CM; Lazo JS; Pollack IF; Begley TJ; Sobol RW
Mol Cancer Res; 2012 Dec; 10(12):1580-96. PubMed ID: 23038810
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
